# Query Results

**Query:** credit rating vs financial health

**Timestamp:** 20251020_025652

**Top K:** 5

**Results Found:** 5

---

## Result 1

**Similarity Score:** 0.3736 | **Semantic:** 0.5337 | **Keyword:** 0.0000 | **Rerank:** -1.5735

**Source:** martiniai.md

**Chunk ID:** 7

**Content:**

```
tember 2021 to August 2025: Initially, IBAs default probability was relatively high at around 0.749 but peaked significantly to about 1.555 by July 2022 indicating financial stress during that period[martini.ai]. Correspondingly, the company's credit rating was downgraded from B4 to C1 around May 2022 reflecting deteriorated credit quality before stabilizing back to B4 by mid-2023[martini.ai]. This period coincides with broader challenges faced by healthcare technology firms amid global economic
```

---

## Result 2

**Similarity Score:** 0.3755 | **Semantic:** 0.5239 | **Keyword:** 0.0293 | **Rerank:** -1.6757

**Source:** martiniai.md

**Chunk ID:** 12

**Content:**

```
from September 2021 to January 2022 [martini.ai]. However, in May 2022, the company experienced a credit rating downgrade to C1, reflecting a decline in its credit quality [martini.ai]. The downgrade from B4 to C1 in May 2022 mirrors the financial stress indicated by the peak in default probability around the same time. The C1 rating persisted with some fluctuations until February 2023, after which the rating migrated back to B4 [martini.ai].
```

---

## Result 3

**Similarity Score:** 0.3853 | **Semantic:** 0.5504 | **Keyword:** 0.0000 | **Rerank:** -1.9649

**Source:** martiniai.md

**Chunk ID:** 14

**Content:**

```
ike the ProteusONE compact proton therapy system. In summary, the credit risk data for IBA indicates a period of financial stress in 2022, evidenced by both the peak in default probability and the credit rating downgrade [martini.ai]. However, the subsequent decline in default probability and the return to a B4 rating suggest improving fundamentals and a stabilization in recent quarters [martini.ai]. This improvement may be attributed to IBA's recovery efforts or improved market conditions within the healthcare technology sector.
```

---

## Result 4

**Similarity Score:** 0.3898 | **Semantic:** 0.5568 | **Keyword:** 0.0000 | **Rerank:** -4.1968

**Source:** martiniai.md

**Chunk ID:** 58

**Content:**

```
d on current macro environment up till mid-2025]. Overall, IBA's macro-driven credit profile appears to be moderately influenced by broader economic conditions, with equity market performance and inflation trends being key factors to monitor. Thus monitoring these two macro factors will be essential since they materially influence borrowing costs, cost structures, and ultimately financial stability metrics underpinning corporate debt ratings within health care tech subsectors.
```

---

## Result 5

**Similarity Score:** 0.3445 | **Semantic:** 0.4921 | **Keyword:** 0.0000 | **Rerank:** -4.3820

**Source:** martiniai.md

**Chunk ID:** 25

**Content:**

```
upporting ongoing investments and debt servicing. The equity-to-assets ratio further underscores a solid equity base 1. Considering these financial indicators, IBA demonstrates a healthy financial state characterized by steady revenue growth, profitability, liquidity, manageable leverage, operational efficiency, and strong cash flow generation. While specific credit ratings and beta values are not detailed in the provided sources, the overall financial performance suggests stability and a low de
```

---

